- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
The PROPEL® advantage
How It Works
Innovative yet intuitive.
-
PROPEL Delivery System is directed to the open surgical cavity.
-
The PROPEL implant's spring-like design conforms to patient's unique anatomy and props open the sinus.
-
Sustained, local release of mometasone furoate over 30 days.*
-
Eventually dissolves.
The PROPEL system leverages Sustained Release Technology, which allows for local, sustained drug delivery directly to the sinus mucosa. Mometasone furoate is embedded in a highly customized polymer, which controls the release of drug over time as the implant dissolves. The self-expanding nature of PROPEL ensures the implant props open the cavity and apposes the tissue to maximize targeted drug delivery.
* Data on file

